Brachytherapy device developer Xoft of Sunnyvale, CA, has received clearance from the U.S. Food and Drug Administration (FDA) for applicators to be used with its Axxent electronic brachytherapy system for the treatment of endometrial cancer.
Previously cleared for accelerated treatment of early-stage breast cancer, Axxent is designed to deliver localized, nonradioactive, isotope-free radiation treatment in minimally shielded clinical settings.
Axxent also recently received expanded FDA clearance for use in the treatment of other cancers or conditions where radiation therapy is indicated.
Related Reading
Xoft medical director wins Gotham's Ira Sohn prize, April 4, 2008
FDA clears Xoft brachytherapy device, March 17, 2008
Xoft reports new CPT code, July 26, 2007
Xoft reaches milestone, April 25, 2007
FDA clears Xoft brachytherapy unit, January 5, 2006
Copyright © 2008 AuntMinnie.com
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
